StockMarketWire.com - Healthcare investment company Syncona reported a 7.2% loss for the six months to the end of September as its portfolio was weighted down by a fall in the share price of one of its holdings.
Autolus, a NASDAQ-listed therapeutics company, declined by 61% during the period, outweighing significant returns that Syncona banked from the sale of Blue Earth Diagnostics and Nightstar, as well as a Series B financing in Achilles Therapeutics. Syncona said it continued to believe in Autolus' strong fundamentals.
Net assets at 30 September 2019 totalled £1,336.8m, down from £1,455.1m at the end of March.
Syncona's capital base increased by £455.8m to £855.5m during the period, and it expects to deploy £200-250m for the full financial year.
Story provided by StockMarketWire.com
Shares Magazine
Shares is the leading weekly publication for retail investors. It is packed with investment ideas, news and educational material to help build and run portfolios and get more from your money.
Investor Events
Shares puts on free Investor Events throughout the year across the country. They provide an opportunity for investors to learn more about companies on the stock market and hear from a range of investment experts including fund managers and Shares journalists.